Physiologically based pharmacokinetic modeling for nanoparticle toxicity study

Methods in Molecular Biology

Volumn 926, Issue , 2012, Pages 369-382

  Li, Mingguang ^a   Reineke, Joshua ^b  

^a Optimum Energy LLC   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

ADME; Biodistribution; Blood flow limited; Membrane limited; PBPK; Pharmacokinetics; Toxicology

Indexed keywords

CHEMICAL COMPOUND; NANOPARTICLE;

AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BODY FLUID; COMPARTMENT MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; ENZYME DEGRADATION; HUMAN; INTERNALIZATION; MAXIMUM PLASMA CONCENTRATION; MOLECULAR RECOGNITION; MOLECULE; NANOTOXICOLOGY; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHYSIOLOGICALLY BASED PHARMACOKINETIC; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; WRITING;

EID: 84934437010     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-2-1_24     Document Type: Article

References (36)

1. Marquis BJ, Love SA, Braun KL et al (2009) Analytical methods to assess nanoparticle toxicity. Analyst 134:425-439
2. Ings RM (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20:1201-1231
3. Seaton A, Tran L, Aitken R, Donaldson K (2010) Nanoparticles, human health hazard and regulation. J R Soc Interface 7(Suppl 1): S119-129
4. Riviere JE (2009) Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:26-34
5. Nestorov I (2007) Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235-249
6. Willmann S, Hohn K, Edginton A et al (2007) Development of a physiology-based wholebody population model for assessing the in fluence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34:401-431
7. Li M, Al-Jamal KT, Kostarelos K et al (2010) Physiologically-based pharmacokinetic modeling of nanoparticles. ACS Nano 4(11):6303-17
8. Kwon KI (1987) Development of physicological pharmacokinetic model. Arch Pharm Res 10:250-257
9. Sturm R (2007) A computer model for the clearance of insoluble particles from the tracheobronchial tree of the human lung. Comput Biol Med 37:680-690
10. Nestorov IA, Aarons LJ, Arundel PA et al (1998) Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 26:21-46
11. Wilhelm C, Gazeau F, Roger J et al (2002) Interaction of anionic superparamagnetic nanoparticles with cells: kinetic analyses of membrane adsorption and subsequent internalization. Langmuir 18:8148-8155
12. Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908
13. Davies B, Morris T (1993) Physiologicalparameters in laboratory-animals and humans. Pharm Res 10:1093-1095
14. Lankveld DP, Oomen AG, Krystek P et al (2010) The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials 31:8350-8361
15. Davda JP, Jain M, Batra SK et al (2008) A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401-413
16. Hagens WI, Oomen AG, de Jong WH et al (2007) What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 49:217-29
17. Evans MV, Dowd SM, Kenyon EM et al (2008) A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid in mice. Toxicol Sci 104:250-260
18. Baxter LT, Zhu H, Mackensen DG et al (1995) Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55:4611-4622
19. MacCalman L, Tran CL, Kuempel E (2009) Development of a bio-mathematical model in rats to describe clearance, retention and translocation of inhaled nanoparticles throughout the body. J Phys: Conf Ser 151:012028
20. Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103-1127
21. Lee HA, Leavens TL, Mason SE et al (2009) Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. Nano Lett 9:794-749
22. Pegaz B, Debefve E, Ballini JP et al (2006) Effect of nanoparticle size on the extravasation and the photothrombic activity of meso(p- tetracarboxyphenyl) porphyrin. J Photochem Photobiol B 85:216-222
23. Nishioka Y, Yoshino H (2001) Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 47:55-64
24. Tassa C, Duffner JL, Lewis TA et al (2010) Binding affinity and kinetic analysis of targeted small molecule-modi fied nanoparticles. Bioconjug Chem 21:14-19
25. Lin JH, Sugiyama Y, Awazu S et al (1982) In vitro and in vivo evaluation of the tissue-toblood partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm 10:637-647
26. Lin P, Chen JW, Chang LW et al (2008) Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. Environ Sci Technol 42:6264-670
27. Stern ST, Hall JB, Yu LL et al (2010) Translational considerations for cancer nanomedicine. J Control Release 146:164-174
28. Videira MA, Botelho MF, Santos AC et al (2002) Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 10:607-613
29. Hussain N, Jaitley V, Florence AT (2001) Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 50:107-142
30. Reddy ST, van der Vlies AJ, Simeoni E et al (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 25:1159-1164
31. Hofmann AF, Molino G, Milanese M et al (1983) Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile-acids in man -cholic-acid in healthy man. J Clin Invest 71:1003-1022
32. Okon E, Pouliquen D, Okon P et al (1994) Biodegradation of magnetite dextran nanoparticles in the rat-a histologic and biophysical study. Lab Invest 71:895-903
33. Anderson JM, Shive MS (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5-24
34. Yang RS, Thomas RS, Gustafson DL et al (1998) Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling. Environ Health Perspect 106(Suppl 6):1385-1393
35. Lu Y, Rieth S, Lohitnavy M et al (2008) Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1- trichloroethane. Regul Toxicol Pharmacol 50:49-60
36. Liao CM, Liang HM, Chen BC et al (2005) Dynamical coupling of PBPK/PD and AUCbased toxicity models for arsenic in tilapia Oreochromis mossambicus from blackfoot disease area in Taiwan. Environ Pollut 135:221-233